CDC25C KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2 and 2 bp insertion in exon2.
Images
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Knockout validation
- Sanger Sequencing, Western blot
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2 and 2 bp insertion in exon2.
Alternative names
Cdc 25C, Cell division cycle 25 homolog C, Cell division cycle 25C, Cell division cycle 25C protein, Dual specificity phosphatase Cdc25C, M-phase inducer phosphatase 3, MPIP3_HUMAN, Mitosis inducer CDC25, PPP1R60, Phosphotyrosine phosphatase, protein phosphatase 1, regulatory subunit 60
What's included?
Recommended products
CDC25C KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2 and 2 bp insertion in exon2.
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Knockout validation
- Sanger Sequencing, Western blot
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2 and 2 bp insertion in exon2.
- Disease
- Adenocarcinoma
- Concentration
Properties
- Gene name
- CDC25C
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Sanger Sequencing, Western blot
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 2 US: 2
- Adherent/suspension
- Adherent
- Gender
- Female
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
Cdc25C also known as dual specificity phosphatase Cdc25C is a 65-kDa protein that acts as a cell cycle regulator controlling the transition from the G2 to M phase. The protein is expressed in various tissues but has higher expression levels in actively dividing cells. Cdc25C is important for cell division due to its ability to activate cyclin-dependent kinases (CDKs) by dephosphorylating the inactive phosphorylated forms. This action makes Cdc25C an important target for regulating the cell cycle and ensuring proper cell proliferation.
- Biological function summary
The proper function of Cdc25C involves facilitating proper cell cycle progression by coordinating with other cell cycle regulators. It participates in a complex network where it dephosphorylates and activates CDK1/cyclin B1 complexes promoting the mitotic entry. This function is important for maintaining genomic stability during cell division. Misregulation of Cdc25C can lead to cell cycle arrest or uncontrolled cell proliferation highlighting its essential role in cell cycle control mechanisms.
- Pathways
Cdc25C fits into the cell cycle checkpoint pathways and is also a part of the DNA damage response pathways. It connects with the p53 and ATM/ATR signaling proteins while responding to DNA damage ensuring a temporary pause in cell cycle progression for repair mechanisms to act. Proper interaction with these pathways is essential for maintaining cellular integrity and preventing the proliferation of damaged cells with CDK1 and Wee1 kinase serving as major interacting proteins in these processes.
- Associated diseases and disorders
Misregulation or overexpression of Cdc25C can relate to cancer and various cell proliferation disorders. In cancer Cdc25C's disordered expression often links to unchecked cell division and tumor progression commonly involving proteins such as p53 which act as tumor suppressors. Furthermore abnormalities in Cdc25C function may lead to issues related to cell cycle progression errors implicating it in other proliferative disorders such as hyperplasia where it acts in conjunction with and alters the activities of proteins like cyclin B1.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
4 product images
Western blot - Human CDC25C knockout HeLa cell lysate (ab257387)
Lane 1: Wild-type HeLa cell lysate (20µg)
Lane 2: CDC25C knockout HeLa cell lysate (20µg)
Lanes 1- 2: Merged signal (red and green). Green - Anti-Cdc25C antibody [E302] ab32444 observed at 58 kDa. Red - loading control Anti-GAPDH antibody [6C5] - Loading Control ab8245 observed at 37 kDa.
Anti-Cdc25C antibody [E302] ab32444 Anti-Cdc25C antibody [E302] was shown to specifically react with Cdc25C in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line Human CDC25C knockout HeLa cell line ab265189 (knockout cell lysate ab257387) was used. Wild-type and Cdc25C knockout samples were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. Anti-Cdc25C antibody [E302] ab32444 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) were incubated overnight at 4°C at 1 in 1000 and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.All lanes: Western blot - Anti-Cdc25C antibody [E302] (Anti-Cdc25C antibody [E302] ab32444) at 1/1000 dilution
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: CDC25C knockout HeLa cell lysate at 20 µg
Lane 2: Western blot - Human CDC25C knockout HeLa cell line (Human CDC25C knockout HeLa cell line ab265189)
Performed under reducing conditions.
Predicted band size: 53 kDa
Observed band size: 58 kDa
Western blot - Human CDC25C knockout HeLa cell lysate (ab257387)
Lane 1: Wild-type HeLa cell lysate (20µg)
Lane 2: CDC25C knockout HeLa cell lysate (20µg)
Lanes 1- 2: Merged signal (red and green). Green - Anti-Cdc25C antibody [E303] ab32050 observed at 58 kDa. Red - loading control Anti-GAPDH antibody [6C5] - Loading Control ab8245 observed at 37 kDa.
Anti-Cdc25C antibody [E303] ab32050 Anti-Cdc25C antibody [E303] was shown to specifically react with Cdc25C in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line Human CDC25C knockout HeLa cell line ab265189 (knockout cell lysate ab257387) was used. Wild-type and Cdc25C knockout samples were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. Anti-Cdc25C antibody [E303] ab32050 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) were incubated overnight at 4°C at 1 in 1000 and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.All lanes: Western blot - Anti-Cdc25C antibody [E303] (Anti-Cdc25C antibody [E303] ab32050) at 1/1000 dilution
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: CDC25C knockout HeLa cell lysate at 20 µg
Lane 2: Western blot - Human CDC25C knockout HeLa cell line (Human CDC25C knockout HeLa cell line ab265189)
Performed under reducing conditions.
Predicted band size: 53 kDa
Observed band size: 58 kDa
Sanger Sequencing - Human CDC25C knockout HeLa cell lysate (ab257387)
Allele-2: 2 bp insertion in exon2
Sanger Sequencing - Human CDC25C knockout HeLa cell lysate (ab257387)
Allele-1: 1 bp insertion in exon2
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com